Identification | Back Directory | [Name]
Vadadustat | [CAS]
1000025-07-9 | [Synonyms]
CS-2486 AKB-6548 PG1016548 PG-1016548 PG 1016548 Vadadustat PG-1016548;AKB-6548 Vadadustat USP/EP/BP Vadadustat (AKB-6548) Vadadustat(AKB-6548/PG-1016548) PG-1016548; PG1016548; PG 1016548; AKB-6548 Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]- AKB-6548; AKB 6548; AKB6548; PG-1016548; PG 1016548; PG1016548; B-506; B506; VADADUSTAT | [Molecular Formula]
C14H11ClN2O4 | [MDL Number]
MFCD30470233 | [MOL File]
1000025-07-9.mol | [Molecular Weight]
306.7 |
Chemical Properties | Back Directory | [Melting point ]
172-174°C | [Boiling point ]
674.6±55.0 °C(Predicted) | [density ]
1.461±0.06 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.09±0.40(Predicted) | [color ]
Pale Beige to Light Beige | [Stability:]
Hygroscopic |
Hazard Information | Back Directory | [Description]
Vadadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3 (IC50s = 1.1 and 0.39 micromolar, respectively).1 It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum. | [Uses]
Vadadustat is a novel HIF (Hypoxia-inducible factor) stabilizer. It provides an effective anemia treatment in nondialysis-dependent chronic kidney disease. |
|
|